Effect of terbutaline on hyperpnoea-induced bronchoconstriction and urinary club cell protein 16 in athletes

A. J. Simpson,1 E. Tufvesson,2 S. D. Anderson,3 L. M. Romer,1 L. Bjermer,2 and P. Kippelen1

1Centre for Sports Medicine and Human Performance, Brunel University, Uxbridge, United Kingdom; 2Department of Respiratory Medicine & Allergology, Lund University, Lund, Sweden; and 3Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

Submitted 20 June 2013; accepted in final form 4 September 2013

Simpson AJ, Tufvesson E, Anderson SD, Romer LM, Bjermer L, Kippelen P. Effect of terbutaline on hyperpnoea-induced bronchoconstriction and urinary club cell protein 16 in athletes. J Appl Physiol 115: 1450–1456, 2013. First published September 12, 2013; doi:10.1152/japplphysiol.00716.2013.—Repe-ted injury of the airway epithelium caused by hyperpnoea of poorly conditioned air has been proposed as a key factor in the pathogenesis of exercise-induced bronchoconstriction (EIB) in athletes. In animals, the short-acting β2-agonist terbutaline has been shown to reduce dry airflow-induced bronchoconstriction and the associated shedding of airway epithelial cells. Our aim was to test the efficacy of inhaled terbutaline in attenuating hyperpnoea-induced bronchoconstriction and airway epithelial injury in athletes. Twenty-seven athletes with EIB participated in a randomized, double-blind, placebo-controlled, crossover study. Athletes completed an 8-min eucapnic voluntary hyperpnoea (EVH) test with dry air on two separate days 15 min after inhaling 0.5 mg terbutaline or a matching placebo. Forced expiratory volume in 1 s (FEV1) and urinary concentration of the club cell (Clara cell) protein 16 (CC16, a marker of airway epithelial perturbation) were measured before and up to 60 min after EVH. The maximum fall in FEV1 of 17 ± 8% (SD) on placebo was reduced to 8 ± 5% following terbutaline (P < 0.001). Terbutaline gave bronchoprotection (i.e., post-EVH FEV1 fall <10%) to 22 (81%) athletes. EVH caused an increase in urinary excretion of CC16 in both conditions (P < 0.001), and terbutaline significantly reduced this rise (pre- to postchallenge CC16 increase 416 ± 495 pg/μmol creatinine after placebo vs. 315 ± 523 pg/μmol creatinine after terbutaline, P = 0.016). These results suggest that the inhalation of a single therapeutic dose of terbutaline offers significant protection against hyperpnoea-induced bronchoconstriction and attenuates acute airway epithelial perturbation in athletes.

exercise-induced bronchoconstriction; epithelial injury; inhaled β2-agonist; Clara cell

EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB) is defined as a transient narrowing of the airways that occurs during or shortly after strenuous exercise. The main stimulus for EIB is evaporative water and heat loss from the airway surface as a consequence of heating and humidifying large volumes of unconditioned air (2). Whereas EIB can be found in both the general population and in athletes, the latter are more at risk for EIB (11), and they often develop EIB later in life (16). We have previously proposed that, in athletes, EIB is a consequence of repeated injury and repair of the airway epithelium in response to long hours of conditioning air during strenuous training (3).

During exercise, as ventilation increases, the conditioning of inspired air extends progressively toward the peripheral airways. If the replacement of water to the airway surface is insufficient, dehydration injury of the distal airways may occur (3). In addition, mechanical stress associated with high airflow and/or bronchoconstriction may accelerate disruption of the epithelial cell layer (24). Following epithelial injury, bulk plasma may leak from the microcirculation to repair the damage to the epithelial cells (35). The process of plasma exudation could then expose the airway smooth muscle to substances that alter its growth and affect its contractile properties, leading to the development of airway hyperresponsiveness and EIB in susceptible individuals (3). In support of this idea, increased levels of bronchial epithelial cells have been found in induced sputum of asthmatic patients with EIB (18), as well as in various athletic populations (elite swimmers (8) and recreational runners (12)]. Increases in tenascin expression and inflammatory cell counts in the lung biopsies of elite cross-country skiers (23) and of elite swimmers (7) have also provided direct evidence of exercise-induced airway remodeling (a sign of repeated injury-repair) and inflammation. Using the concentration of the lung-specific club cell (Clara cell) protein (CC16) in extrapulmonary fluids, our group previously established that dry air hyperpnoea causes an acute perturbation of the airway epithelium (6). Consistent with our finding, serum and urinary CC16 concentration have also been shown to increase following bouts of cycling (9), running (12, 29), and swimming (10, 17, 37). In swimming, however, because of the noxious effect of trichloramines on club cell function (10), exposure to chlorination by-products may act as a confounder (27). In our recent study on running (5), we showed that inhalation of warm humid air attenuated the rise in urinary CC16 postexercise (likely as a result of a reduced water loss from the airway surface). We are now aiming to establish whether pharmacological agents also have the potency to blunt, or even to completely abolish, the CC16 response associated with exercise hyperpnoea.

In a healthy human epithelium, airway surface liquid is mainly regulated via apical Cl− secretion and Na+ absorption [passive flow of water occurring along the osmotic gradient (21)]. Pharmacological interventions can modify ion transport. In vitro, the β2-agonist terbutaline has been shown to increase the transport of Cl− toward the airway lumen (14). Moreover, in canine peripheral airways challenged with dry air, infusion of terbutaline attenuated airway narrowing and reduced epithelial cell shedding (40). To date, the impact of pharmacological agents administered directly to the airways has not been tested. We reasoned that, if terbutaline facilitates replacement of water at the airway surface level during exposure to dry air, pretreat-
ment with inhaled terbutaline may attenuate hyperpnoea-induced airway injury in humans.

In this study, we tested the efficacy of a single dose of inhaled terbutaline at reducing hyperpnoea-induced airway epithelial perturbation in athletes. We also aimed to confirm the bronchoprotective effect of terbutaline in athletes with EIB. Our hypothesis was that 0.5 mg terbutaline will attenuate the increase in urinary concentration of CC16 and the fall in forced expiratory volume in 1 s (FEV1) following 8 min of eucapnic voluntary hyperpnoea (EVH) with dry air in athletes.

METHODS

Subjects. The study population consisted of 27 athletes with EIB. EIB was confirmed by a fall of ≥10% in FEV1 following an 8-min EVH challenge during a screening visit. Participants were nonsmokers, free from respiratory infections for 4 wk before the study, and with no known chronic medical condition other than asthma or EIB. Regular swimmers (>1 h/wk) were excluded. Participants abstained from alcohol, caffeine, and exercise on the day of testing, and medication was withheld as follows: short-acting β2-agonist (SABA) treatments were withheld for a minimum of 8 h, long-acting β2-agonist (LABA) treatments for 24 h, inhaled corticosteroid (ICS) treatments for 12 h, and combination therapies of LABA + ICS for 24 h (28). Written informed consent was obtained from all participants after the study protocol, and potential risks were explained. The study was approved by the United Kingdom National Health Service Research Ethics Committee (NHS REC reference no.: 10/H0716/30).

Experimental design. The study used a randomized, double-blind, placebo-controlled, crossover experimental design. All participants attended two experimental visits, separated by at least 2 days but no more than 3 wk, during which they were administered either 0.5 mg of terbutaline or a placebo 15 min before completion of an EVH challenge. The primary end points were changes in urinary CC16 concentration and FEV1.

Experimental visits were conducted in the morning between 8:00 and 11:00 A.M. [to standardize for fluctuations in CC16 levels throughout the day (4)] and started with the recording of baseline lung function. The active drug (i.e., 0.5 mg of terbutaline) was administered via a dry powder inhaler (Bricanyl Turbohaler; Astra Zeneca, London, UK). An empty demonstration Turbohaler was used for administration of the placebo. Subjects were instructed to take one deep, hard inhalation of the drug or placebo and to hold their breath for 10 s. Posttreatment lung function manoeuvres were repeated at 10 min. The EVH challenge started 15 min after treatment. Spontaneous recovery of FEV1 to baseline levels following the EVH challenge was measured at 2, 5, 10, 15, 20, 30, and 60 min.

Subjects ingested 200 ml of water 1 h before each visit. They ingested a further 400 ml upon arrival at the laboratory and then 200 ml at 30-min intervals. Two baseline urine samples were obtained: the first, on arrival at the laboratory, which was discarded; the second, 30–60 min later and immediately before administration of the drug, which was used as baseline. Further urine samples were collected 30 and 60 min after the EVH challenge. All samples were stored, without preservatives, at −80°C. Atopic status was tested by skin prick testing during the first experimental visit, with the procedure starting 40 min post-EVH.

CC16 analysis. To avoid prostatic contamination, the first 100 ml of urine were systematically discarded in male participants (4). CC16 was measured using the Human Clara Cell Protein ELISA kit from BioVendor (Modrice, Czech Republic) according to the manufacturer’s instructions. The detection limit for CC16 was 20 pg/ml. All urine samples were analyzed for creatinine using a COBAS 6000 analyzer (Roche Diagnostics, Bromma, Sweden). CC16 results were expressed as picograms of excreted mediator per micromole of creatinine.
Bronchodilator effect (P/H9252). Placebo Lung function results Table 2. Small (5 line lung function parameters (Table 2). Terbutaline had a There was no difference between experimental visits in base-

post-EVH averaged 19 1452 Effect of Terbutaline on Bronchoconstriction and Urinary CC16•

volume in 1 s expressed relative to the predicted value (36); EIB, exercise-induced bronchoconstriction; SABA, short-acting 2-agonist; ICS, inhaled corticosteroids; combination, combination therapy of LABA and ICS; post-EVH maximum FEV1 fall, maximal fall in FEV1 after eucapnic voluntary hyperpnoea; protection, % bronchoprotection afforded by terbutaline. ***Significantly different from placebo (P < 0.001).

>80% predicted in all participants, and the fall in FEV1 post-EVH averaged 19 ± 10% (Table 1). Baseline lung function and ventilation level during EVH. There was no difference between experimental visits in baseline lung function parameters (Table 2). Terbutaline had a small (5 ± 3% increase in FEV1) but statistically significant bronchodilator effect (P < 0.001, Table 2). FEF25–75%, FEF25, FEF50, FEF75, and PEF also significantly increased postadministration of terbutaline (P < 0.001), whereas FVC remained unchanged (Table 2). No significant change in lung function was observed following administration of the placebo (Table 2). Minute ventilation was slightly but significantly larger in the terbutaline condition compared with the placebo condition: 102 ± 20 vs. 101 ± 20 (P = 0.047). Participants reached

Table 2. Lung function results

<table>
<thead>
<tr>
<th>Lung Function Measurement</th>
<th>Pre-Rx</th>
<th>Post-Rx</th>
<th>Post-EVH, min value</th>
<th>Pre-Rx vs. Post-Rx (P Value)</th>
<th>Post-Rx vs. Post-EVH (P Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1, l</td>
<td>3.68 ± 0.65</td>
<td>3.67 ± 0.67</td>
<td>3.06 ± 0.68</td>
<td>0.316</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FVC, l</td>
<td>4.74 ± 0.93</td>
<td>4.76 ± 0.95</td>
<td>4.48 ± 1.04</td>
<td>0.798</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF25–75%, l/s</td>
<td>3.27 ± 0.90</td>
<td>3.27 ± 0.90</td>
<td>2.17 ± 0.69</td>
<td>0.741</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF25, l/s</td>
<td>6.18 ± 1.23</td>
<td>6.12 ± 1.23</td>
<td>4.39 ± 1.30</td>
<td>0.495</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF50, l/s</td>
<td>3.57 ± 0.86</td>
<td>3.71 ± 0.98</td>
<td>2.47 ± 0.78</td>
<td>0.478</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF75, l/s</td>
<td>1.70 ± 0.90</td>
<td>1.63 ± 0.58</td>
<td>1.02 ± 0.39</td>
<td>0.866</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PEF, l/s</td>
<td>8.15 ± 1.48</td>
<td>8.15 ± 1.44</td>
<td>6.45 ± 1.65</td>
<td>0.968</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Terbutaline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1, l</td>
<td>3.65 ± 0.64</td>
<td>3.82 ± 0.68</td>
<td>3.43 ± 0.63</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FVC, l</td>
<td>4.74 ± 0.94</td>
<td>4.73 ± 0.95</td>
<td>4.62 ± 0.95</td>
<td>0.796</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF25–75%, l/s</td>
<td>3.26 ± 0.93</td>
<td>3.17 ± 0.97</td>
<td>3.07 ± 0.86</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF25, l/s</td>
<td>6.15 ± 1.32</td>
<td>6.78 ± 1.41</td>
<td>5.57 ± 1.32</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF50, l/s</td>
<td>3.77 ± 1.06</td>
<td>4.22 ± 1.33</td>
<td>3.45 ± 0.84</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEF75, l/s</td>
<td>1.62 ± 0.61</td>
<td>2.16 ± 1.43</td>
<td>1.47 ± 0.50</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PEF, l/s</td>
<td>7.95 ± 1.41</td>
<td>8.27 ± 1.50</td>
<td>7.38 ± 1.31</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Pre-Rx: pretreatment with either 0.5 mg terbutaline or placebo; Post-Rx: posttreatment; Post-EVH: min value, lowest value recorded after 8 min of eucapnic voluntary hyperpnoea of dry air; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FEF25–75%, mean forced expiratory flow between 25 and 75% of FVC; FEFx, forced expiratory flow at x% of FVC; PEF, peak expiratory flow.
80 ± 8% MVV during the terbutaline visit and 78 ± 7% MVV during the placebo visit (P = 0.022).

**Airway response to EVH.** Terbutaline significantly inhibited the airway response to EVH. The maximum fall in FEV₁ was reduced from 17 ± 8% in the placebo condition to 8 ± 5% in the terbutaline condition (P < 0.001, Table 1). FEV₁-AUC₀–₆₀ was significantly reduced following terbutaline administration: from 425 ± 283 to 163 ± 146% min (P < 0.001, Fig. 1). The bronchoprotection offered by terbutaline for the maximum percent fall in FEV₁ and FEV₁_AUC₀–₆₀ was 54 ± 28% (range 0–94%, Table 1) and 60 ± 30% (range 0–100%), respectively. Terbutaline provided complete protection (i.e., post-EVH maximum %fall in FEV₁ <10%) to 22 of the 27 participants (81%).

EVH caused a significant decrease in FVC and in all expiratory flow values in both conditions (P < 0.001, Table 2). The decrease in FVC post-EVH was significantly attenuated with the administration of terbutaline (from 0.28 ± 0.19 to 0.12 ± 0.11 l, P < 0.001).

**Urinary CC16.** Three participants were excluded from the urinary CC16 statistical analysis, since their CC16 concentrations were below the detection point. In addition, one participant was excluded on the grounds of being an outlier. His CC16 measurements were highly variable at baseline (2,457 and 1,055 pg/µmol creatinine in the placebo and terbutaline condition, respectively), and he was the only participant to display a reduction in urinary CC16 excretion postchallenge in both the placebo and terbutaline condition (−1,582 and −261 pg/µmol creatinine, respectively). The total number of data analyzed for CC16 was therefore 23.

Baseline urinary CC16 was not significantly different between conditions: 266 ± 329 in the placebo condition vs. 267 ± 292 pg/µmol creatinine in the terbutaline condition (P = 0.695). EVH caused a significant increase in urinary excretion of CC16 in both conditions (P < 0.001), but the peak urinary release of CC16 postchallenge was significantly attenuated by terbutaline: from 682 ± 788 to 582 ± 741 pg/µmol creatinine (P = 0.032). The magnitude of the change in urinary CC16 (pre- to maximum postchallenge CC16) was also significantly reduced after premedication with terbutaline (from 416 ± 495 to 315 ± 523 pg/µmol creatinine, P = 0.016; Fig. 2).

Repeated-measures ANOVA revealed significant time (P < 0.001) and interaction (P = 0.002) effects, which indicate that terbutaline altered the kinetics of urinary CC16 excretion. Post hoc analysis revealed that urinary CC16 increased significantly from baseline to 30 and 60 min post-EVH in both conditions (P < 0.01). However, in the placebo condition, urinary CC16 continued to increase between 30 and 60 min of recovery (P = 0.033), whereas it started to plateau at 30 min of recovery in the terbutaline condition. As a result, urinary concentrations of CC16 were significantly lower in the terbutaline condition at 60 min recovery compared with placebo (P = 0.007, Fig. 3).

---

**Fig. 1.** Mean ± SE percentage changes from baseline (Pre-Rx) in forced expiratory volume in 1 s (FEV₁) after inhalation (Post-Rx) of 0.5 mg terbutaline (●) or placebo (○), and up to 60 min after eucapnic voluntary hyperpnoea (EVH) of dry air in athletes with exercise-induced bronchoconstriction. Post-EVH the area under the FEV₁ time curve (measured from post-Rx) was significantly reduced following administration of terbutaline (P < 0.001).

**Fig. 2.** Maximum change in urinary excretion of CC16 following EVH of dry air after pretreatment with placebo or 0.5 mg of terbutaline in athletes with exercise-induced bronchoconstriction. Individual values with means (95% confidence intervals). *P < 0.05.

**Fig. 3.** Mean ± SE urinary CC16 concentrations at baseline and 30 and 60 min post-EVH of dry air following pretreatment with 0.5 mg terbutaline (●) or placebo (○) in athletes with exercise-induced bronchoconstriction. *P < 0.05, **P < 0.01, and ***P < 0.001.
DISCUSSION

The aim of this study was to test the efficacy of inhaled terbutaline at reducing hyperpnoea-induced airway epithelial injury and bronchoconstriction in athletes. We showed that a single therapeutic dose of terbutaline of 0.5 mg was able to blunt the rise in urinary CC16 concentration following hyperpnoea of dry air. Moreover, we confirmed that terbutaline provided a significant degree of bronchoprotection to the majority (81%) of the athletes. These results demonstrate the potential for inhaled β2-agonists to attenuate, not only bronchoconstriction, but also acute airway epithelial perturbation in athletes with EIB.

This study supports our previous findings that hyperpnoea of dry air causes perturbation to the airway epithelium in athletes (6). It is also consistent with work conducted by our group (5) and others (9, 10, 37) that showed that exercise hyperpnoea is associated with an increase in serum and urinary concentration of CC16 in athletes. The ability of parenteral β2-agonists to reduce dry air-induced epithelial injury was previously demonstrated in animals (33, 40). We have now extended these findings by demonstrating that terbutaline can attenuate airway epithelial perturbation when administered by inhalation in the human lungs.

Airway epithelial perturbation in this study was assessed through changes in urinary CC16 concentration. CC16 is a protein secreted from the club cells located primarily in the distal airways (38). Acute increases in the concentration of CC16 in extrapulmonary fluids have previously been proposed to reflect a transient loss of the lung epithelial barrier integrity (20). An increase in urinary CC16 may also represent an increase in CC16 production/secretion by club cells in an attempt to modulate local inflammatory reactions (22). We have previously shown that hyperpnoea of dry air is associated with mast cell activation and inflammatory mediator release in athletes (26). Therefore, the rise in urinary CC16 following EVH in the current study may be the result of a combination of increased leakage of CC16 across the airway epithelium and increased production and/or secretion of the protein at the club cell level.

The use of a noninvasive marker (with multiple sampling time points) enabled us to test, for the first time, the efficacy of a pharmacological agent at attenuating hyperpnoea-induced airway perturbation in athletes. We showed that in urinary CC16 concentration following a short period of hyperpnoea of dry air was significantly blunted with premedication with terbutaline. In vitro, terbutaline has been shown to increase the flow of Cl− toward the airway lumen (14), an action likely to be mediated through binding of the drug with β2-receptors on epithelial cells and subsequent release of cAMP (39). Our research team previously demonstrated that reduction of the dehydration stress to the airways through inhalation of warm humid air limits epithelial cell perturbation after exercise (5). Similarly, in the current study, we propose that the reduction in urinary CC16 excretion post-EVH was the result of reduced dehydration of the airway epithelium mediated through terbutaline-enhanced water secretion.

An alternative interpretation of the results is that terbutaline did not affect the severity of epithelial perturbation per se but rather enhanced the speed of epithelial cell repair. Perkins et al. (34) showed in vitro that salbutamol stimulated both wound repair and spreading and proliferation of human lung epithelial cells. The potential of β2-agonists to stimulate epithelial cell repair may explain why, in our study, urinary CC16 continued to increase between 30 and 60 min of recovery in the placebo condition, whereas it started to plateau in the terbutaline condition. We propose that terbutaline was able to stimulate the repair of the epithelial cells before the later time point (at 60 min), and therefore reduced leakage of CC16 across the airway epithelial barrier.

A third contributing factor to our results could be the effect of terbutaline on the bronchial vascular system. In a murine model, terbutaline given in the instillate (intratracheally) reduced microvascular permeability during high-volume ventilation (15). β2-agonists are thought to mediate vascular permeability, either directly [by relaxing the endothelial contractile proteins and thereby reducing gaps between endothelial cells (41)] or indirectly [by inhibiting vasoactive mediator release from the lung mast cells (13)]. We therefore cannot exclude that terbutaline, by reducing vascular leakage, limited the passage of CC16 in the bloodstream post-EVH.

Terbutaline in the present study was delivered through a dry powder inhaler (Turbuhaler). When delivered via Turbuhaler, terbutaline is known to reach all levels of the tracheobronchial tree, including the small airways (30). In our study, we noticed a significant increase in all forced expiratory flow parameters (including FEF50 and FEF75) postadministration of terbutaline. This is relevant in that the recruitment of the smaller airways in the conditioning of inspired air has been highlighted as the main mechanism for exercise-induced airway epithelial injury (3). Terbutaline has the potential to enhance osmotic-driven water flux to the airway lumen (14). Enhancement of water secretion to the larger airways may have therefore reduced the necessity for the smaller airways to be recruited in the conditioning process and may have protected those smaller airways against epithelial injury. The dispersion of terbutaline within the airways is known to be dependent on the inspiratory flow achieved with the Turbuhaler (31). Because inspiratory flow was not controlled in our study, interindividual differences in dispersion of the medication may account for the variation in the effectiveness of the terbutaline in attenuating the rise in CC16 post-EVH.

Although there was little difference in ventilation rates achieved by the athletes between the terbutaline and the placebo conditions, bronchoconstriction was more severe after placebo inhalation. Therefore, in our control condition, significant compressive stress may have occurred within the airways (32), which may have further compromised the integrity of the airway epithelial barrier. However, we did not find any significant correlation between the changes in urinary excretion of CC16 and the fall in FEV1 post-EVH under our two experimental conditions (data not shown). Similarly, in some of our previous work (5, 6), there was no difference in magnitude of urinary CC16 increase following exercise or EVH challenge tests in individuals with and without EIB. This therefore suggests that mild-to-moderate bronchoconstriction per se is unlikely to affect the extent of perturbation to the airway epithelium.

This paper is relevant to endurance athletes who are thought to repeatedly damage their airways through dehydration stress (3). Endurance (aerobic) athletes have an increased prevalence of EIB compared with their counterparts who perform anaer-
obic exercise and with the general population (11). Repeated
airway epithelial injury-repair has been highlighted as a key
factor contributing to the increased prevalence of airway hy-
perresponsiveness in elite endurance athletes (3). Strategies
aiming at preventing hypopnoea-induced epithelial perturba-
tion may therefore be beneficial in the prevention of EIB (25).

Here, we showed that terbutaline acutely reduces airway epi-
thelial perturbation. Chronic use of inhaled β2-agonist may,
however, cause tachyphylaxis and failure to respond to emer-
gency bronchodilator treatment (19). Therefore, alternative
treatments that act via similar pathways to β2-agonists should
be explored to devise appropriate long-term prevention strate-
gies for airway injury in athletes.

In conclusion, this study demonstrates for the first time that
premedication with a single, inhaled dose of terbutaline re-
duces hypopnoea-induced airway epithelial perturbation in
athletes. The evidence presented also provides further support
to the use of terbutaline for prevention of EIB in athletes. We
propose that terbutaline reduces epithelial perturbation mainly
by enhancing water movement toward the airway lumen and by
stimulating repair of the damaged airway epithelial cells.

Because of the potential side effects of chronic use of inhaled
β2-agonists, we recommend that further research into the
prevention of airway injury in athletes is conducted, targeting
drugs that either enhance ion transport or stimulate epithelial
cell repair.

ACKNOWLEDGMENTS

We thank Dr. Aldona Greenwood for help with the data collection.

GRANTS

The study was funded by the World Anti Doping Agency.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

Author contributions: A.J.S., E.T., and P.K. performed experiments; A.J.S.,
E.T., and P.K. analyzed data; A.J.S. and P.K. interpreted results of experi-
ments; A.J.S. prepared figures; A.J.S. drafted manuscript; A.J.S., E.T., S.D.A.,
L.M.R., L.B., and P.K. approved final version of manuscript; E.T., S.D.A.,
L.M.R., L.B., and P.K. edited and revised manuscript; S.D.A. and P.K.
conception and design of research.

REFERENCES

1. Anderson SD, Argyros GJ, Magnusson H, Holker K. Provocation by
eucapnic voluntary hypopnoea to identify exercise induced bronchoc-
2. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma
3. Anderson SD, Kippelen P. Exercise-induced bronchocstriction: patho-
4. Anderson L, Lundberg P, Barregard L. Methodological aspects on
measurement of Clara cell protein in urine as a biomarker for airway
5. Bolger C, Tufvesson E, Anderson SD, Devereux G, Ayres J, Bjernar
L, Sue-Chu M, Kippelen P. Effect of inspired air conditions on exercise-
induced bronchoconstriction and urinary CC16 levels in athletes. J Appl
L, Kippelen P. Hyperpnoea-induced bronchoconstriction and urinary
M, Chakir J, Boulet LP. Airway remodeling and inflammation in
competitive swimmers training in indoor chlorinated swimming pools.
8. Bourgault V, Turnel J, St-Laurent J, Bertrand M, Boulet L. Asthma,
airway inflammation and epithelial damage in swimmers and cold-air
9. Broekhuizen R, Alvesofe PM, Del Giacco SR, Drobnic F. Exercise-
induced asthmatic response: respiratory and allergic disorders in elite
athletes: epidemiology, mechanisms and diagnostic: part I of the report
from the joint task force of the European respiratory society (ERS) and
the European academy of allergy and clinical immunology (EAACI) in
10. Church MK, Hiroi J. Inhibition of IgE-dependent histamine release
from human dispersed lung mast cells by anti-allergic drugs and salbutamol.
11. Davis B, Marin YM, Yee JE, Nadel JA. Effect of terbutaline on
movement of Cl– and Na+ across trachea of the dog in vitro. Am Rev
12. de Frost N, Dreyfuss D, Ricard J, Saumon G. Terbutaline lessens
protein fluxes across the alveolar-capillary barrier during high-volume
13. Fitch K. Beta(2)-agonists at the olympic games. Clin Rev Allergy Immu-
14. Font-Ribera L, Kogevas M, Zock J, Gómez FP, Barreiro E, Nieu-
wenhuijzen MJ, Fernandez P, Lourenccetti C, Pérez-Olabarría M,
Bustamante M, Marcos R, Grimalt JO, Villanueva CM. Short-term
changes in respiratory biomarkers after swimming in a chlorinated pool.
immunopathology of asthma with exercise-induced bronchoconstriction.
MA. B2-agonist tolerance and exercise-induced bronchospasm. Am J
17. Hermans C, Bernard A. Lung epithelial-specific proteins: characteris-
tics and potential applications as markers. Am J Respir Crit Care Med
19. Jorens PG, Sibille Y, Goulding NJ, Van Overveld FJ, Herman AG,
Bossaert L, De Backer WA, Lauwers Y, Flower RJ, Bernard A.
Potential role of Clara cell protein, an endogenous phospholipase A2
20. Karjalainen EM, Laitinen A, Sue-Chu M, Altraja A, Bjernar L,
Laitinen LA. Evidence of airway inflammation and remodeling in ski
athletes with and without bronchial hyperresponsiveness to methacholine.
23. Legerkvest BJ, Bernard A, Blomberg A, Bergstrom E, Forsberg B,
Holmstrom K, Karp K, Lundstrom NG, Segerstedt B, Svensson M,
Nordberg G. Pulmonary epithelial integrity in children: Relationship to
ambient ozone exposure and swimming pool attendance. Environ Health
24. Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A,
Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R,
Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF,


